A robust liquid chromatography-tandem mass spectrometry (LC-MS-MS) method has been developed and validated for the determination of lidocaine (LIDO) and its metabolite (monoethylglycinexylidide (MEGX)) in serum. One hundred microliters of bovine serum were spiked with LIDO-d10 as internal standard and deproteinized with acetonitrile prior to solid-phase extraction purification using strong cation exchange cartridge. The chromatographic separation was achieved on a BetaBasic-18 column with a mobile phase consisting of aqueous 0.1% formic acid and 0.1% formic acid in acetonitrile. The instrumental linearity was verified from 0.4 to 1,000 ng/mL obtaining determination coefficients (r 2 ) of >0.99. The limit of quantification (LOQ) was set at 1 ng/mL for both LIDO and MEGX. The coefficients of variation for within-and between-batch imprecision, including LOQ, were ≤10% and the percentage of inaccuracy was <15%. The absolute recoveries were >75% for both analytes. Experiments demonstrated the method applicability to sera of different animal species and also to plasma, urine and milk matrices.
Introduction
Lidocaine (LIDO) is widely used in human and veterinary practice as local anesthetic, analgesic and antiarrhythmic agent (1) (2) (3) (4) , and it was the first amino amide-type local anesthetic synthesized under the name Xylocaine in 1943. LIDO is de-ethylated, by the cytochrome P450 system, to monoethylglycinexylidide (MEGX), a metabolite that retains pharmacological and toxicological activity similar to LIDO, although less powerful (5, 6) . The entity of the MEGX formation after LIDO administration is considered a valid test to evaluate the hepatic functionality (5, 7) .
Various analytical methods, describing the determination of LIDO and its active metabolite, have been published based on highperformance liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) (3, 6, (8) (9) (10) (11) (12) (13) . Other techniques as liquid chromatography coupled to UV detection or gas chromatography have been reported (14) (15) (16) (17) ; however, they are not able to assure limits of quantification <20 ng/mL in serum or plasma. Generally, the sample treatment of biological fluids is carried out by applying liquidliquid extraction (LLE) or, for plasma, protein precipitation (PP) with organic solvents or acids. In this work, a sample treatment using solid-phase extraction (SPE) based on strong cation exchange (SCX) is described. Considering the importance to define the pharmacokinetic profiles of LIDO in various species after different route of administration and the utility of MEGX determination in order to evaluate the hepatic function, this work deals with the development and validation of a flexible analytical method suitable for the analysis of various biological fluids (serum, plasma, urine and milk) belonging to different animal species. purity) from Sigma-Aldrich (St. Louis, MO, USA) and lidocaine-d10 (IS) from CDN isotopes (Poole, UK). Stock solutions of LIDO, MEGX and LIDO-d10 were prepared at 1 mg/mL in methanol and stored at approximately −20°C for 6 months. Mixed working solutions of LIDO and MEGX were prepared at 10, 1, 0.1 and 0.01 µg/mL in methanol. LIDO-d10 working solutions were prepared at 10 and 1 µg/mL in methanol. Working solutions were stored at −20°C for 7 days.
Sample preparation
One hundred microliters of serum or plasma were placed in a 2 mL propylene tube and spiked with 10 µL of IS solution at 1 µg/mL in methanol (100 ng/mL). Then 1 mL of acetonitrile was added, the tube vortexed and centrifuged at 14,000 r.p.m. for 5 min (centrifuge Model 5810R, Eppendorf, Hamburg, Germany). The supernatant was transferred to 15-mL polypropylene centrifuge tube and the extraction step was repeated with other 0.5 mL of acetonitrile. The organic extracts were diluted with 10 mL of formic acid 0.1% and vortexed. For urine, about 1 mL of sample was centrifuged (4,500 r.p.m. for 5 min) and then 100 µL of supernatant was spiked with IS as mentioned above and directly diluted with 5 mL of formic acid 0.1%. Similarly, after IS addition, 100 µL of milk was diluted with 5 mL of formic acid 0.1% and centrifuged at 14,000 r.p.m. for 5 min prior to SPE loading.
Strata-X-C cartridges (60 mg/3 mL) were conditioned with 2 mL of methanol followed by 2 mL of formic acid 0.1%. After the loading of the sample, each cartridge was washed with 2 mL of formic acid 0.1% and 2 mL of methanol. The analytes were eluted with 2 mL of MeOH/NH 3 80/20 (v/v) and evaporated under a nitrogen stream at 40°C. The residue was dissolved in 250 µL of formic acid 0.1%/ acetonitrile 80/20 (v/v), filtered with a 0.45 µm membrane Polytetrafluoroethylene filter and transferred to an autosampler vial.
LC-MS-MS conditions
Liquid chromatographic separation and mass spectrometric detection were performed on a LC-MS-MS system consisting of a Finnigan Surveyor LC pump combined with a triple quadrupole TSQ Quantum Ultra mass spectrometer via electrospray ionization (ESI) interface (Thermo Fisher, Palo Alto, CA, USA). The chromatographic separation was done by a BetaBasic-18 analytical column (150 × 2.1 mm, 5 µm) connected with the guard cartridge BetaBasic-18 (10 × 2.1 mm, 5 µm) obtained from Thermo Electron Corporation (Waltham, MA, USA). HPLC eluent A was water and eluent B was acetonitrile both containing 0.1% (v/v) formic acid. The gradient was initiated with 5% eluent B for 1 min, continued with linear increase to 35% B in 3.5 min; this condition was maintained for 4.5 min and was followed by a linear increase to 95% B in 1 min. This condition was maintained for 2 min. Finally, the system returned to 5% B in 1 min and was re-equilibrated for 2 min. The column temperature was 30°C and the sample temperature was kept at 16°C. The flow rate was 0.3 mL/min and the injection volume 10 µL.
For MS detection, the ESI source was operated in positive-ion mode and run with Xcalibur 2.0 software (Thermo Fisher). Highpurity nitrogen was used as the sheath (40 AU) and auxiliary (5 AU) gas and high-purity argon was used as the collision gas (1.5 mTorr). The parameters were as follows: spray voltage, 3.5 kV; capillary temperature, 270°C; scan width for selected reaction monitoring (SRM), 0.5 m/z; scan time, 0.25 s. The peak width settings for both Q1 and Q3 were 0.7 m/z. The SRM ion pair transitions and collision energy levels of analytes and IS are listed in Table I .
Method validation
The validation study was carried out according to the bioanalytical method validation guidance of United States Food and Drug Administration (FDA) (18) . Commission Decision 2002/657/EC concerning the performance of analytical methods and the interpretation of results for the determination of residues in live animals and their products was also considered (19) .
The identification of analytes in a sample was based on the following selectivity criteria: (i) the signal-to-noise ratio for each product ion was >3 : 1, (ii) the relative retention time of the individual product ions in the sample matched the mean retention time of the product ions in the standards within 2.5% and (iii) the area ratio obtained from the product ions of the analyte in the sample and in the standards was within the values listed in Table 4 of Commission Decision 2002/657/EC (19) .
The instrumental linearity was investigated in the concentration range 0.4-1,000 ng/mL injecting 16 solutions in formic acid 0.1%/ acetonitrile 80/20 (v/v). Calibration curves were generated by using the ratios of the analyte peak area to the IS peak area (y) versus analyte concentrations (x) and were fitted into the equation of y = bx + a (linear regression).
The precision and accuracy were determined by analyzing five independently spiked bovine serum samples at each quality control (QC) level (50, 500 and 1,000 ng/mL) and at the limit of quantification (LOQ = 1 ng/mL) in one batch. The four spiking levels (1, 50, 500 and 1,000 ng/mL) were prepared progressively adding to 100 µL of serum 10, 50, 50 and 10 µL of the mixed solution of LIDO and MEGX at 0.01, 0.1, 1 and 10 µg/mL, respectively. The IS was added at 100 ng/mL (10 µL of the LIDO-d10 solution at 1 µg/mL). Subsequently, the three QC samples and the samples fortified at LOQ were extracted five times in one additional batch by a different operator. On each occasion, separate calibration curves in solvent and in matrix (calibration curve) were acquired. Matrix-matched curve was prepared adding the analytes and IS immediately prior to LC injection. Method applicability to sera of different animal species was tested comparing the results observed at 50 ng/mL in bovine serum during the validation study with the results obtained at the same level in horse, dog, pig and sheep sera (19) . In addition, the same experiment was repeated testing the method performances at 50 ng/mL in avian plasma, bovine urine and bovine milk.
Results

Chromatographic separation
The LC-MS-MS chromatograms obtained from blank bovine serum and from the same serum spiked with 1 ng/mL of MEGX and LIDO are shown in Figure 1 . In the blank sample, an interfering peak was found in the window of MEGX; however, its retention time (6.4 min) did not correspond to that of analyte.
Method validation
The whole procedure was applied to at least six blank samples of each matrix and species to verify the method selectivity, and it was shown that no interfering compounds were observed around the retention times of the two analytes.
The instrumental linearity (solvent) was verified in the range from 0.4 to 1,000 ng/mL (r 2 > 0.99) and for all the 16 injected standard solutions, the deviation between the calculated and the nominal concentration was <15% (18) . To evaluate the method limits, preliminary experiments were carried out in bovine sera spiked at low concentrations of LIDO and MEGX, i.e., at concentrations considered near the expected limit of detection: 0.25, 0.5, 0.75 and 1.0 ng/mL. For each of these four levels, five replicates were performed, and for each level, the standard deviation of the concentrations was multiplied for the appropriate coverage factor (20) . For both analytes, the estimated LOD and LOQ were ∼0.3 and 1.0 ng/mL, respectively. Accordingly, method precision and accuracy were checked starting from 1 ng/mL (LOQ) to 1,000 ng/ mL (1, 50, 500 and 1,000 ng/mL) as reported in Table II . The withinbatch coefficients of variation (CV r ) were in the range 3.1-9.3 and 4.3-8.5% for LIDO and MEGX, respectively, whereas the betweenbatch coefficients of variation (CV R ) were in the range 3.1-9.3% (LIDO) and 6.9-10% (MEGX). The absolute recoveries (extraction efficiency) were evaluated comparing the peak area of the analytes Figure 1 . LC-MS-MS chromatograms of a blank bovine serum sample (a) and of the same bovine serum sample spiked at 1 ng/mL of LIDO and MEGX (IS at 100 ng/mL). This figure is available in black and white in print and in color at JCS online.
in the 10 sera spiked at each validation level (1, 50, 500 and 1,000 ng/ mL) and their peak area in the matrix-matched standard at the relevant concentration. These recoveries were ≥76% (LIDO) and 88% (MEGX). For accuracy, the mean value was within 15% of the actual value. Matrix effects were assessed dividing the area ratio (analyte/IS) in blank matrix spiked after extraction with analyte by the same ratio measured in the solvent standard solutions (×100) at the four validation levels. The values ranged from 99 to 104%, demonstrating the IS efficiency to correct matrix effects.
Stability assays were carried out in the QC samples at the lowest and highest concentration (50 and 1,000 ng/mL) investigating concentration differences after three freeze-and-thaw cycles and after 24 h in the LC-MS-MS autosampler (16°C). Taken into account the method precision (between-batch reproducibility limit), the observed differences were not significant and so, from all the results in Table III , LIDO and MEGX were found to be stable.
Additionally 35 experiments were carried out to extend method applicability to sera belonging to other animal species (dog, horse, pig and sheep). This applicability was assessed comparing samples spiked at 50 ng/mL. Avian plasma, bovine urine and bovine milk were also tested (Table IV) . The obtained mean accuracies were compared by analysis of variance (ANOVA) among the eight groups including bovine sera acquired during the validation study. No significant differences emerged (P = 0.11 and 0.16 for LIDO and MEGX, respectively).
Analysis of incurred dog sera
The developed procedure has been applied to the quantification of LIDO in the sera of six anesthetized dogs undergoing arthroscopic surgery. The dogs were premedicated with 10 µg/kg of intramuscular acepromazine, then general anesthesia was induced by 4-6 mg/kg of propofol and maintained with isoflurane in oxygen. Before the beginning of surgery, LIDO 2% plus adrenalina 1 : 100,000 was administered by intra-articular route. Blood samples were taken at prefixed time points ( preadministration of LIDO, 5, 10, 15, 30, 60, 90, 120, 180, 240 and 360 min after LIDO inoculum) to evaluate the absorption of the local anesthetic into the systemic circulation. At the end of anesthesia, 0.2 mg/kg of meloxicam via subcutaneous route was administered to assure an adequate post-surgical analgesia. The LC-MS-MS chromatograms of sera of one of the six anesthetized dogs collected at two different times after LIDO administration are shown in Figure 2 . After 10 min, only LIDO was present at 22 ng/mL (a), whereas at 120 min, both LIDO (159 ng/mL) and MEGX (30 ng/mL) were detected.
Discussion
Owing to their basic nature, chromatographic peak shapes of LIDO and MEGX may result in asymmetry due to peak tailing (6, 8) . The factors controlling peak shape and retention of basic compounds are related to the number and type of free silanols (silanol acidity) in the LC stationary phase. The end-capped BetaBasic-18 column with a highly deactivated phase provided satisfactory chromatographic peaks with acceptable symmetry for both the analytes.
The pK a s of LIDO and MEGX are ∼7.9; therefore at pH <6, both are fully ionized. This characteristic has been used for the application of the strong cation exchange mechanism (SCX SPE) to purification purposes. As a matter of fact, the ionic exchange mechanism is more selective than LLE or SPE based on other sorbents (21) . In addition, porous polymer ion exchange resin as Strata-X-C has a higher exchange capacity and a wider pH operating range than silica-based materials. This selectivity enabled to achieve low limits of quantification also starting from low amount (100 µL) of sample thanks to the cleanliness of the final extract. The SPE elution volume was optimized (2 mL) reducing the evaporation time. Accordingly, the percentage of the aqueous solution of concentrated ammonia in the SPE elution mixture was also verified, determining that the minimum percentage for a complete elution of LIDO and MEGX was 20% (Figure 3 ). After optimization, the proposed sample treatment involves a short analysis time: an operator can process up to 24 samples in ∼5 h. In Table V , the main published methods for LIDO and MEGX determination in biological fluids by LC-MS-MS are compared with the here reported procedure. Almost all methods apply LLE or PP to purify Standard deviation (SD R ) and coefficient of variation (CV R ) estimated in between-batch experiments (ANOVA). samples, except Nelis et al. (12) who use cation exchange SPE (CSDAU). CSDAU sorbent is a silica-based mixed-mode phase (octyl and benzyl sulfonic acid) involving a more complex treatment than the polymeric phases. Horse plasma or urines were loaded after dilution with phosphate buffer ( pH 6) and mixtures containing chloroform and dichloromethane were used in SPE washing and elution steps, respectively (12) . In our method, the control of pH was not necessary and sample treatment was very simple. Milk and urine were directly diluted with a formic acid solution (0.1%), whereas serum and plasma were diluted after PP; the same acid solution was used in the washing step and no chlorinated solvents were necessary.
Pharmacokinetic studies on LIDO have been carried out mainly in human plasma and serum (8, 9, 11, (13) (14) (15) (16) (17) ; on the other hand, in the literature studies several animal species and matrices have been also reported (1, 3, 6, 10, 12) . Therefore, our aim was to develop a rapid procedure with demonstrated applicability to a lot of species/matrices. This is not necessarily true for the Nelis et al. protocol (12) in which samples were concentrated 10 times (1 mL of horse urine or plasma was suspended in a final volume of 100 µL prior to LC injection) with more interfering compounds in the final extract.
The protocol reported by Nelis et al. (12) was specific for horse urine and plasma and has not demonstrated applicable for other Bovine milk (n = 5) LIDO 97 ± 5 99 ± 2 100 ± 1 100 ± 1 100 ± 2 98 ± 2 101 ± 4 102 ± 1 MEGX 108 ± 9 105 ± 11 113 ± 3 100 ± 7 104 ± 9 102 ± 6 109 ± 5 107 ± 3 Figure 2 . LC-MS-MS chromatograms of sera of an anesthetized dog administered with LIDO (a) after 10 min and (b) after 120 min (IS at 100 ng/mL). This figure is available in black and white in print and in color at JCS online.
species or matrices. It may not be useful for other matrices as it uses a 10-fold concentration (1 mL of horse urine or plasma was suspended in a final volume of 100 µL prior to LC injection), which may yield a lot of interfering compounds in the final extract. It is well recognized that labeled internal standards largely improve method accuracy and precision. However, interferences may arise from the use of internal standards containing native analyte as impurities. Therefore, prior to introducing LIDO-d10 in the operative protocol, its purity was checked. In Figure 4 , the highresolution spectra of LIDO (a) and of LIDO-d10 (b) show that no impurities of LIDO ([M+H] + ion, m/z 235.1801) were found in the labeled analog LIDO-d10 ([M+H] + ion, m/z 245.2429). As expected, since the internal standard is the labeled analog of LIDO, a slightly better accuracy for the parent drug than for its metabolite is observed: MEGX accuracies are generally >100% (108-114%) due to the higher absolute recovery of metabolite than that of LIDO and LIDO-d10 (see also Figure 3 ). Nevertheless, for both the analytes, method accuracy and precision agree with the requirements of FDA guidelines (18) being within 15%. Also the stability tests were successfully passed. The bovine serum has been used as a model biological fluid for the full validation study (40 experiments at 4 validation levels). However, since the protocol provided the application of a dilution factor (100 µL of serum to a final volume of 250 µL) with labeled internal standard, selective purification (SCX SPE) and selective detection (triple quadrupole analyzer), applicability experiments were carried out in seven different combinations of matrix/species: serum/dog, serum/horse, serum/pig, serum/sheep, plasma/chicken, urine/cow and milk/cow. The comparison of the accuracies obtained in the main validation study (bovine serum) and in the different combinations did not reveal significant differences (ANOVA). Finally, the sera analysis of treated dogs demonstrated that method works well in incurred samples also in the presence of other administered drugs. 
Conclusion
A simple method for the determination of LIDO and its main metabolite in biological fluids has been developed and validated. The main advantage of the reported procedure is its flexibility permitting to analyze a wide range of concentrations, in various biological fluids (serum, plasma, urine and milk) starting from a low amount of sample. On the other hand, the achieved quantification limits are suitable to investigate low concentrations of LIDO and MEGX, and therefore, the procedure is able to describe the pharmacokinetic profiles obtained during different studies applying different LIDO administration routes and doses irrespective of animal species. Moreover, the amount of analyzed sample could be further reduced (e.g., 10 µL), enabling the possibility of analysis also when the availability of the biological fluid is very limited as in pediatric studies or in studies carried out on small animals (13).
